{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:14:44Z","timestamp":1648664084748},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-017-1436-7","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T10:46:17Z","timestamp":1504781177000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Linda","family":"Sakhri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Pinsolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Pluchart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,16]]},"reference":[{"key":"1436_CR1","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3543\u201351.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1436_CR2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","volume":"9","author":"M Hazarika","year":"2004","unstructured":"Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (alimta). Oncologist. 2004;9:482\u20138.","journal-title":"Oncologist"},{"key":"1436_CR3","first-page":"110","volume":"303","author":"ME Kuzur","year":"1980","unstructured":"Kuzur ME, Greco FA. Cisplatin-induced anemia. N Engl J Med. 1980;303:110\u20131.","journal-title":"N Engl J Med"},{"key":"1436_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9\u201323.","journal-title":"Cancer Treat Rev"},{"key":"1436_CR5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdl154","volume":"17","author":"H Maase von der","year":"2006","unstructured":"von der Maase H. A phase II trial of pemetrexed plus gemcitabine in locally advanced and\/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17:1533\u20138.","journal-title":"Ann Oncol"},{"key":"1436_CR6","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.23503","volume":"112","author":"R Dreicer","year":"2008","unstructured":"Dreicer R, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the eastern cooperative oncology group. Cancer. 2008;112:2671\u20135.","journal-title":"Cancer"},{"key":"1436_CR7","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","volume":"24","author":"CJ Sweeney","year":"2006","unstructured":"Sweeney CJ, Phase II. Study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451\u20137.","journal-title":"J Clin Oncol"},{"key":"1436_CR8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/bjc.2014.591","volume":"112","author":"YJ Choi","year":"2015","unstructured":"Choi YJ, et al. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10\u201317). Br J Cancer. 2015;112:260\u20135.","journal-title":"Br J Cancer"},{"key":"1436_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10637-006-9020-9","volume":"25","author":"MD Galsky","year":"2007","unstructured":"Galsky MD, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265\u201370.","journal-title":"Invest New Drugs"},{"key":"1436_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10637-007-9111-2","volume":"26","author":"TE Hutson","year":"2008","unstructured":"Hutson TE, et al. Phase I study of a 3-drug regimen of gemcitabine\/cisplatin\/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs. 2008;26:151\u20138.","journal-title":"Invest New Drugs"},{"key":"1436_CR11","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1158\/1078-0432.CCR-05-2644","volume":"12","author":"K Hendricksen","year":"2006","unstructured":"Hendricksen K. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs. Clin Cancer Res. 2006;12:2597\u2013601.","journal-title":"Clin Cancer Res"},{"key":"1436_CR12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44:372\u201380.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T10:46:20Z","timestamp":1504781180000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1436-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,16]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1436-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,16]]},"article-number":"262"}}